drugset / Trial / NCT01112085

MIcrodoses of raNIbizumab in Diabetic MAcular Edema (MINIMA-2)

NCT01112085

RandomizedParallel-groupSingle-blindTreatment

Summary

The objective of this study is to investigate if the drug ranibizumab administrated by microdose injection into the eye is safe and effective to treat diabetic macular edema.

Timeline

Start
2010-04
Primary completion
2014-01
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Ranibizumab Monoclonal antibody 0.05 mg Intravitreal
Subject Ranibizumab Monoclonal antibody 0.5 mg Intravitreal